SOURCE: Sirona Biochem Corp.

Sirona Biochem Corp.

October 25, 2016 17:30 ET

Sirona Biochem CEO to Present at French Consulate and Business in France Roundtable Event

VANCOUVER, BC--(Marketwired - October 25, 2016) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") is pleased to announce that CEO, Dr. Howard Verrico, has been invited by the Consulate of France in Vancouver and Business in France to present at a roundtable breakfast event at the Terminal City Club on October 26th, 2016.

The event will showcase opportunities for business in France and Canadian entrepreneurs. Dr. Verrico will speak on successfully completing and managing the acquisition of TFChem in France, the extensive government support received, the multiple licensing agreements the company has accomplished and the future of Sirona/TFChem.

Other speakers will include the French Ambassador, H.E. Mr. Nicolas Chapuis and Mr. Philippe Huberdeau, Minister Counselor for Economic Affairs.

For more information about this event: https://investinfrance.eventbrite.com

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Contact Information

  • For more information regarding this press release, please contact:

    Christopher Hopton
    CFO
    Sirona Biochem Corp.
    Phone: 1.604.282.6064
    Email: chopton@sironabiochem.com